Frontlight ResearchEarly access
What researchers published on Neuroblastoma
10,750 papers, newest first.
Showing 20 of 165
Randomised trialEfficacy of anti-GD2 antibody immunotherapy with filgrastim and teceleukin versus standard treatment with sargramostim, aldesleukin and isotretinoin in children with high-risk neuroblastoma.International journal of clinical oncology
In plain wordsRead moreRead the paper on PubMedTrial resultThe First-in-Human ENCIT01 Trial Comparing Second- versus Third-Generation L1CAM-specific CAR T Cells in Patients with Primary Refractory or Relapsed Neuroblastoma.Clinical cancer research : an official journal of the American Association for Cancer Research
In plain wordsRead moreRead the paper on PubMedTrial resultFraction-dependent dose dynamics and clinical safety in high-risk neuroblastoma treated with [177Lu]Lu-DOTATATE: results from the LuDO-N trial.European journal of nuclear medicine and molecular imaging
In plain wordsRead moreRead the paper on PubMedTrial resultBintrafusp alfa for patients with recurrent or metastatic olfactory neuroblastoma.Cancer immunology, immunotherapy : CII
In plain wordsRead moreRead the paper on PubMedTrial resultImmune Response and Safety of Anti-NeuGcGM3 Anti-Idiotype Vaccine Racotumomab in Patients With High-Risk Neuroblastoma: An Open-Label, Single-Arm, Multicenter Phase 2 Study in Argentina.Pediatric blood & cancer
In plain wordsRead moreRead the paper on PubMedTrial resultA phase II trial of naxitamab plus stepped-up dosing of GM-CSF for patients with high-risk neuroblastoma in second or later complete remission.International journal of cancer
In plain wordsRead moreRead the paper on PubMedTrial resultThe Effect of Digital Therapy-Based Aerobic Exercise on Children With Neuroblastoma: Protocol for a Prospective Controlled Trial.JMIR research protocols
Trial resultPhase 1/2 Study of Crizotinib in Children With Relapsed/Refractory ALK-Positive Anaplastic Large Cell Lymphoma or Neuroblastoma in Japan.Cancer science
In plain wordsRead moreRead the paper on PubMedRandomised trialDinutuximab Beta Added to Temozolomide-Based Chemotherapy for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON Immuno Phase II Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology
In plain wordsRead moreRead the paper on PubMedTrial resultNaxitamab plus stepped-up dosing of granulocyte-macrophage colony-stimulating factor for primary refractory high-risk neuroblastoma: results of a phase I/II trial.Journal of hematology & oncology
In plain wordsRead moreRead the paper on PubMedTrial resultA Phase I Trial of Nab-Paclitaxel in Combination With Gemcitabine for Relapsed/Refractory Pediatric Solid Tumors.Pediatric blood & cancer
Randomised trialIncidence and survival among children with neuroblastoma in Spain over 22 years.BMC cancer
Trial resultGD2-targeting CAR T cells in high-risk neuroblastoma: a phase 1/2 trial.Nature medicine
Trial resultFcγ Receptor Polymorphism in Patients with Relapsed/Refractory High-Risk Neuroblastoma Correlates with Outcomes in the SIOPEN Dinutuximab Beta Long-Term Infusion Trial.Clinical cancer research : an official journal of the American Association for Cancer Research
Trial resultPhase I Study of 131I-Metaiodobenzylguanidine With Dinutuximab ± Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Trial resultEx vivo-expanded and activated haploidentical natural killer cells infusion before autologous stem cell transplantation in high-risk neuroblastoma: a phase I/II pilot study.Cancer immunology, immunotherapy : CII
Trial resultA Phase II Trial of Naxitamab plus Stepped-up Dosing of GM-CSF for Patients with High-Risk Neuroblastoma in First Complete Remission.Clinical cancer research : an official journal of the American Association for Cancer Research
Trial resultFrequency and Clinical Significance of Clonal and Subclonal Driver Mutations in High-Risk Neuroblastoma at Diagnosis: A Children's Oncology Group Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Trial resultLong-term outcomes of GD2-directed CAR-T cell therapy in patients with neuroblastoma.Nature medicine
Trial resultThe anti-GD2 monoclonal antibody naxitamab plus GM-CSF for relapsed or refractory high-risk neuroblastoma: a phase 2 clinical trial.Nature communications